The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia

被引：0
作者：
Valentina Gianfelici
Luciano Levato
Stefano Molica
机构：
[1] Azienda Ospedaliera Pugliese-Ciaccio,Department Hematology
来源：
Current Hematologic Malignancy Reports | 2020年 / 15卷
关键词：
Chronic lymphocytic leukaemia; B cell receptor inhibitors; Venetoclax; Combination strategies; Indefinite treatment; Time-fixed therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：343 / 349
页数：6
相关论文
共 125 条
  • [41] Shanafelt TD(2019)Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL Blood 134 851-undefined
  • [42] Wang XV(2016)A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies Blood 127 411-undefined
  • [43] Kay NE(2019)Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from arm C of the Sequoia (BGB-3111-304) trial. [Abstract] Blood 134 499-undefined
  • [44] Byrd JC(2019)Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis Clin Lymphoma Myeloma Leuk 19 423-undefined
  • [45] Brown JR(undefined)undefined undefined undefined undefined-undefined
  • [46] O’Brien S(undefined)undefined undefined undefined undefined-undefined
  • [47] Brown JR(undefined)undefined undefined undefined undefined-undefined
  • [48] Hillmen P(undefined)undefined undefined undefined undefined-undefined
  • [49] O'Brien S(undefined)undefined undefined undefined undefined-undefined
  • [50] Winqvist M(undefined)undefined undefined undefined undefined-undefined
12345678910